Introduction: Streptococcus pyogenes is a gram-positive, pathogenic bacterium which causes a variety of diseases including streptococcal pharyngitis, impetigo and rheumatic heart disease, depending on which tissue it infects. Many Terminalia spp. have documented therapeutic properties as general antiseptics, inhibiting the growth of a wide variety of bacterial species. Methods: Solvent extracts were prepared using Indian Terminalia spp. with documented ethnobotanical usage to treat bacterial infections, or published antibacterial activity. The extracts were investigated by disc diffusion assay for the ability to inhibit the growth of a clinical strain of S. pyogenes. Their MIC values were determined to quantify and compare their efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: T. arjuna, T. catappa and T. chebula methanolic and ethyl acetate extracts displayed potent antibacterial activity in the disc diffusion assay against S. pyogenes. The T. catappa and T. chebula ethyl acetate extracts were particularly potent, with MIC values of 225 and 205 µg/mL respectively. All methanolic extracts were also potent growth inhibitors with MIC values of 268 µg/mL (T. arjuna methanolic extract), 425 µg/mL (T. catappa methanolic extract) and 300 µg/mL (T. chebula methanolic extract). The T. catappa hexane extract was also a potent S. pyogenes growth inhibitor (MIC 768 µg/mL). All other extracts were either ineffective or were of only low efficacy. Furthermore, all of the Indian Terminalia spp. extracts were nontoxic in the Artemia fransiscana bioassay, with LC 50 values >1000 µg/mL. Conclusion: The potent growth inhibitory bioactivity of the methanolic and ethyl acetate T. arjuna, T. catappa and T. chebula extracts against S. pyogenes demonstrates their potential for the treatment and prevention of pharyngitis, impetigo and rheumatic heart disease. All extracts were nontoxic indicating their safety for therapeutic use.
INTRODUCTION
The genus Streptococcus comprises over 50 different species of grampositive, non-sporulating cocci-shaped bacteria. Found in a diverse range of environments including soils, or as part of the natural human microflora, Streptococcus spp. are primarily facultatively anaerobic, however some are obligate anaerobes. 1 Many species within the genus are pathogenic and responsible for an extensive variety of diseases. Pathogens within the genus can infect ruminants, humans or cause disease inboth people and animals. 2 Diseases in humans can vary and range from non-life threatening epithelial/throat infections, such as pharyngitis or skin infections including impetigo and scarlet fever, to potentially fatal internal infections such as pneumonia, necrotizing fasciitis, toxic shock syndrome or meningitis, 3, 4 Some Streptococcus species can also trigger autoimmune rheumatic heart disease. 5 Streptococcus spp. are grouped according to their haemolytic peoperties and Lancefield serotyping. Group A streptococcal pharyngitis is an acute infection of the nasopharynx and/or oropharynx and is initiated through infection by Streptococcus pyogenes. 6 S. pyogenes infections are the most common bacterial cause of pharyngitis and are responsible for up to 33% of all diagnosed cases of sore throat in children, and up to 10% in adults. 7 Though mostly non-life threatening, Group A streptococcal infections are a significant economic burden. Indeed, recent estimates place the societal cost (both medical and nonmedical) in the United States alone ranging from $224 to $539 million dollars annually. 8 While the bacterium responds well to antibiotic treatment, 7 the increasing risk of drug resistance highlights the need to develop alternatives to fight these and other diseases. The probing of natural plant resources for previously undiscovered antibacterial products offers an alternative to the traditional drug design and synthesis. One of the most useful genera of therapeutic plants is Terminalia. This genus encompasses approximately 200-250 species of flowering trees and has extensive uses in multiple traditional medicinal systems. 9 The antibacterial activity of Terminalia spp. has been particularly well reported. Extracts prepared from the fruit of the Australian species Terminalia ferdinandiana (Kakadu plum) have potent growth inhibitory activity against an extensive panel of pathogens including bacteria associated diarrhoea and dysentery 10 as well as the bacterial triggers of rheumatoid arthritis (Proteus mirabilis) 11 and multiple sclerosis (Acinitobacter baylyi and Pseudomonas aeruginosa). 12 Leaf extracts from the same species have also been shown to inhibit growth of the same bacteria, as well as a microbial trigger of ankylosing spondylitis (Klebsiella pneumoniae). 19, 20 Terminalia chebula has traditional uses in Ayurveda for the treatment of numerous diseases and conditions 21 and has potent antibacterial activity. 19 Indeed, a recent study has even highlighted their potential in the prevention and treatment of anthrax. 22 Terminalia alata, Terminalia bellirica and Terminalia catappa also have broad spectrum antibacterial activity. 20 However, despite the wealth of antibacterial studies for Terminalia spp., there is a lack of studies screening Terminalia spp. for the ability to inhibit S. pyogenes growth and thus their therapeutic value for the prevention and treatment of streptococcal pharyngitis, impetigo, rheumatic heart disease etc. Indeed, a literature search only found a single study which reported S. pyogenes growth inhibitory activity for the Indian Terminalia spp. T. chebula. 23 However, whilst anti-Streptococcal activity was reported, the value of that study is limited as the extracts were screened only with a single, relatively high extract concentration. Our study was undertaken to examine the ability of selected Asian Terminalia spp. with extensive usage in Ayurvedic medicine for the ability to inhibit S. pyogenes growth.
MATERIALS AND METHODS

Plant source and extraction
Terminalia arjuna, Terminalia catappa and Terminalia chebula plant materials used throughout this study were kindly provided by Dr. Paran Rayan, Griffith University. Voucher samples of all plant specimens have been stored at the School of Natural Sciences, Griffith University, Brisbane Australia. The plant materials were comprehensively desiccated in a Sunbeam food dehydrator and the dried materials kept at -30 o C until use. Prior to usage, the materials were thawed and ground into a coarse powder.Individual 1 g amounts of the material were weighed into separate tubes and 50 mL of deionised water, methanol, chloroform, hexane and ethyl acetate were added. All solvents were AR grade and were obtained from Ajax, Australia. The ground plant materials were individually extracted in each solvent for 24 h at 4 o C using gentle shaking. The extracts were then filtered through filter paper (Whatman No. 54) under vacuum, followed by drying by rotary evaporation in an Eppendorf concentrator 5301. The resultant extracts were weighed and redissolved in 10 mL deionised water (containing 1 % DMSO).
Qualitative phytochemical studies
Phytochemical analysis of the extracts for the presence of triterpenoids, tannins, saponins, phytosteroids, phenolic compounds, flavonoids, cardiac glycosides, anthraquinones and alkaloids was performed as previously described.
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Antibacterial screening
Clinical Streptococcus pyogenes strain All media was supplied by Oxoid Ltd., Australia. The clinical isolate strain of Streptococcus pyogenes used in this study was donated by Michelle Mendell of the School of Natural Sciences Griffith University, Australia. All growth studies were performed using nutrient agar (Oxoid Ltd., Australia) under aerobic conditions. Incubation was at 37 o C and the stock culture was subcultured and maintained in nutrient broth at 4 o C.
Evaluation of antimicrobial activity
The antimicrobial activity of the T. arjuna, T. chebula and T. catappa plant extracts was assessed using a modified disc diffusion assay as previously described. 16, 27, 28 Briefly, 100 µL of S. pyogenes was grown in 10 mL of fresh nutrient broth until a cell count of ~10 8 cells/mL was attained. A 100 µL volume of bacterial suspension was spread onto nutrient agar plates. The antibacterial activity of the extracts was tested using 5 mm sterilised filter paper discs. Discs were infused with 10 µL of the each individual extract, allowed to dry and placed onto inoculated plates. The plates were allowed to stand at 4 o C for 2 h before incubation at 30 o C for 24 h. The diameters of the inhibition zones were measured in millimetres. All measurements were rounded to the closest whole millimetre. Each assay was performed in at least triplicate. Mean values (± SEM) are reported in this study. Standard discs of ampicillin (10 µg) were obtained from Oxoid Ltd. and served as positive controls for antibacterial activity. Filter discs infused with 10 µL of sterilised water were used as a negative control.
Minimum inhibitory concentration (MIC) determination
The minimum inhibitory concentration (MIC) of each extract was assessed as previously described. 29, 30 Briefly, the plant extracts were diluted in deionised water and tested across a range of concentrations. Discs were infused with 10 µL of the test dilutions, allowed to dry and placed onto inoculated plates. The assay was performed as outlined above and graphs of the zone of inhibition versus concentration were plotted for each extract. Linear regression was used to determine the MIC values of each extract.
Toxicity screening Reference toxin for toxicity screening
Potassium dichromate (K 2 Cr 2 O 7 ) (AR grade, Chem-Supply, Australia) was prepared as a 4 mg/mL solution in distilled water and was serially diluted in artificial seawater for use in the Artemia franciscana nauplii bioassay.
Artemia franciscana nauplii toxicity screening
Toxicity was tested using an adapted Artemia franciscana nauplii lethality assay as previously described. [31] [32] [33] Briefly, 400 µL of seawater containing ~52 (mean=52.3, n=120, SEM=12.6) A. franciscana nauplii were added to wells of a 48 well plate and immediately used for bioassay. A volume of 400 µL of diluted plant extracts or the reference toxin were transferred to the wells and incubated at 25 ± 1 o C under artificial light (1000 Lux). A negative control (400 µL seawater) was run in triplicate for each plate. All treatments were performed in at least triplicate. The wells were checked at regular intervals and the number of dead counted. The nauplii were deemed dead if no movement of the appendages was detected within 10 sec. Following 24 h exposure, all nauplii were sacrificed and counted to determine the total % mortality per well. The LC 50 with 95% confidence limits for each treatment was assessed using probit analysis.
Statistical analysis
Data are expressed as the mean ± SEM of at least three independent experiments.
RESULTS
Liquid extraction yields and qualitative phytochemical screening
Extraction of 1 g of the various dried Terminalia spp. materials with the solvents yielded dried plant extracts ranging from 22 mg (T. arjuna 
+++ indicates a large response; ++ indicates a moderate response; + indicates a minor response; -indicates no response in the assay. F=fruit; B=branch; W=aqueous extract; M=methanolic extract; C=chloroform extract; H=hexane extract; E=ethyl acetate extract. Used externally to treat fungal infections and cutaneous wounds and in the prevention of inflammation of the mucosal membrane of the mouth. Used internally as a laxative and is known for its purgativeeffects. Known to have uses in the treatment of asthma and coughs.
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ethyl acetate leaf extract) to 634 mg (T. chebula methanolic fruit extract) ( Table 2) . Typically, T. chebula fruit extracts gave higher yields compared to T. arjuna and T. catappa extracted materials. However, this trend was not observed in the lower polarity fruit extracts (hexane and chloroform) obtained from T. catappa, which had significantly higher yields compared to those of T. arjuna and T. chebula. Indeed, the T. catappa hexane and chloroform extracts had approximately double the yields when compared to the corresponding methanolic or aqueous extracts. Qualitative phytochemical studies showed that the methanolic and aqueous extracts generally had an extensive range of phytochemicals (Table 2 ). Both these solvents typically extracted greater levels of phenolics (especially water soluble phenolics) for all plant materials. Additionally, these extracts generally yielded high levels of tannins and flavonoids and moderate to high levels of saponins. Similarly, the ethyl acetate extracts had similar phytochemical profiles to the aqueous and methanolic counterparts. However, most classes of compounds were present in only lower relative abundances. Conversely, the chloroform and hexane extracts of most of the Terminalia spp. typically only had low to moderate levels of phenolics, flavonoids and tannins and were generally devoid of detectable levels of the other phytochemical classes.
Antimicrobial activity
To assess the inhibitory activity of the crude plant extracts against S. pyogenes, 10 µL aliquots of each extract were screened using a disc diffusion assay. The bacterial growth was inhibited by 11 of the 15 extracts tested (~73%) (Figure 1 ). The T. catappa ethyl acetate and T. chebula me thanolic extracts were the most potent inhibitors of S. pyogenes growth (as judged by zones of inhibition), with inhibition zones of 13.6 ± 0.7 mm and 14.3 ± 0.7 mm respectively. This compares favourably with the ampicillin control, which had an inhibitory zone of 12.0 ± 1.0 mm. Collectively, T. catappa extracts were the best inhibitors of growth, with all extracts testing positive and the methanolic, chloroform and hexane extracts giving > 9 mm inhibitory zones. The antimicrobial efficacy was further quantified by determining the MIC values (Table 3 ). In general, the ethyl acetate extracts were the most potent inhibitors of S. pyogenes growth, with MIC values of approximately 200 µg/mL (~2 µg infused into the disc). The T. arjuna ethyl acetate extract defied this trend with no growth inhibitory activity evident for this extract at all. However, it is noteworthy that this extract was the least concentrated of the tested extracts and it is possible it may have exhibited activity if tested at a higher concentration. Similarly potent P. pyogenes growth inhibition was also noted for the methanolic extracts of all Terminalia spp. (MIC values 250-400 µg/mL). With the exceptions of the T. arjuna chloroform and hexane extracts, the T. catappa hexane extract and the aqueous T. chebula extract (which displayed moderate growth inhibitory activity), all other extracts were ineffective at inhibiting S. pyogenes growth.
Quantification of toxicity
All extracts were initially screened at 2000 µg/mL in the assay (Figure 2 ). For comparison, the reference toxin potassium dichromate (1000 µg/mL) was also assessed in the bioassay. The potassium dichromate reference toxin was rapid in its onset, inducing nauplii death within the first 3 h of exposure and 100% mortality evident in the subsequent 4-5 h (unpublished results). The methanolic and aqueous extracts of all Terminalia spp. were toxic in the Artemia nauplii bioassay, with ≥50% mortality rates at 24 h. The mortality for all other extracts was not significantly different to the mortality seen for the seawater control.
To further enumerate the effect of toxin concentration on the induction of mortality, the extracts were serially diluted in artificial seawater to test across a range of concentrations in the Artemia nauplii bioassay. 
DISCUSSION
Members of genus Terminalia have been used for a broad range of medicinal purposes by traditional healers from a wide variety of ethnic and cultural groupings. The best documented of these are the traditional Indian medicinal systems, particularly the Ayurveda. Ayurvedic practitioners employ various Terminalia spp. for a wide variety of medicinal purposes including abdominal and back pain, coughs and colds, conjunctivitis, diarrhoea and dysentery, fever, headache, heart disorders, inflammation, leprosy, pneumoniae, sexually transmitted diseases, worms, wounds, haemorrhages, ulcers, and as a general tonic. 9 Many of these diseases are caused by microbial pathogens, indicating the potential of these plants as antiseptic agents and numerous recent investigations have reported on their antibacterial properties. T. arjuna leaf and branch extracts have antibacterial activity against a wide panel of microbes. 9, 19, 20 T. chebula also has a tradition of use in Ayurveda for the treatment of numerous diseases and conditions. 9, 21 T. chebula has also been reported to display potent antibacterial activity against a microbial panel. 19 Similarly, T. alata, T. bellirica and T. catappa have been reported to have broad spectrum antibacterial activity. 20 The growth inhibitory activity of the Indian Terminalia spp. extracts against S. pyogenes is particularly noteworthy for the development of future antibiotic chemotherapeutics. Aside from the obvious antibiotic applications to directly treat localised throat (pharyngitis) and skin infections (impetigo), 6 ,7 a number of substantially more serious illnesses are caused by acute and chronic S. pyogenes infections and may also benefit from treatment with these extracts. When S. pyogenes invades and colonises deeper tissue it can lead to erysipelas and cellulitis, conditions characterised by localised red, swollen and painful areas, and often by fever and lethargy. [2] [3] [4] If not promptly treated, bacterium can spread to other areas via the bloodstream which may result in serious tissue damage and autoimmune diseases such as glomerulonephritis (inflammation of the glomeruli in the kidneys), lymphedema (inflammation of lymph nodes), septic arthritis and rheumatic fever (inflammation of cardiac tissue). [3] [4] [5] Furthermore, acute S. pyogenes infections of subcutaneous tissues can induce the potentially fatal disease necrotizing fasciitis. 4 These conditions are not only highly debilitating, but may also be life threatening and new, more effective treatment regimens could potentially prolong and increase the quality of life as well as reducing the burden on the health system. The efficacy of the Indian Terminalia spp. extracts indicates that they may have potential in the treatment of these illnesses and further investigation is warranted. Whilst an examination of the phytochemistry of the Terminalia spp. was beyond the scope of our study, a commonality of this genus is their relatively high levels of a number of tannin components including exifone (4-galloylpyrogallol), ellagic acid dehydrate, trimethyl ellagic acid, chebulic acid, corilagen, castalagin and chebulagic acid.
9,11-13 Gallotannins have been reported to inhibit the growth of a broad spectrum of bacterial species 34 through a variety of mechanisms including binding cell surface molecules including lipoteichoic acid and proline-rich cell surface proteins, 35, 36 and by inhibiting glucosyltransferase enzymes. 37 Ellagitannins are also highly potent inhibitors of bacterial growth, with MIC values as low as 62.5 µg/ml. 34 Ellagitannins have also been reported to function via several antibiotic mechanisms including interaction with cytoplasmic oxidoreductases and by disrupting bacterial cell walls. 34, 36 It is likely that other phytochemical classes also contribute to the growth inhibitory properties of these extracts. Our qualitative phytochemical screening studies indicate that polyphenolics, flavonoids, saponins, and terpenes were present in the Terminalia spp. extracts. Terpenoids have been previously reported to have potent broad spectrum antibacterial activity 38 and therefore may contribute to the inhibitory activity against S. pyogenes. Many studies have also reported potent antibacterial activities for a wide variety of flavonoids. 39 Further phytochemical evaluation studies and bioactivity driven isolation of active components is required to further evaluate the mechanism of S. pyogenes growth inhibition. The findings reported here also demonstrate that all of the Indian Terminalia spp. extracts tested in our study were nontoxic towards Artemia franciscana nauplii, with LC 50 values substantially >1000 µg/mL. Extracts with LC 50 values >1000 µg/mL towards Artemia nauplii are defined as being nontoxic. 33 Whilst our preliminary toxicity studies indicate that these extracts may be safe for use as S. pyogenes growth inhibitors, studies using human cell lines are required to further evaluate the safety of these extracts.
